Lottie Moss, Mounjaro and What the Headlines Leave Out

Step 1: Understand what the press coverage is (and is not) telling you

When a public figure like Lottie Moss mentions Mounjaro, the story almost always focuses on the visible outcome: weight lost, a changed appearance, a candid interview. What it rarely includes is the clinical pathway that made that treatment legally possible. Mounjaro is not something you can walk into a pharmacy and pick off a shelf. UK law classifies it as a Prescription-Only Medicine, which means a qualified prescriber must assess you, review your medical history and make an independent clinical judgement before a single pen is dispensed.

That process exists for good reason. Tirzepatide is a potent medicine with a specific licensed population. It is not assessed by the MHRA for cosmetic weight loss or for people who are simply looking to lose a few kilograms before an event. The NHS medicines page for tirzepatide sets out, plainly, that it works by slowing gastric emptying and reducing appetite through two separate gut-hormone pathways, biology that operates the same way regardless of who is taking it or why the story ended up in the tabloids.

None of this means celebrity discussion is harmful. Awareness can help people who genuinely qualify explore an option they had not considered. The gap is context, and this page tries to fill it.

Step 2: Know the eligibility criteria that the headlines skip

NICE published its recommendation for tirzepatide in December 2024, updated in September 2025, as Technology Appraisal TA1026. The threshold for NHS access is a BMI of 35 or above, combined with at least one weight-related condition such as hypertension, type 2 diabetes, dyslipidaemia, obstructive sleep apnoea or cardiovascular disease. That is a deliberately specific population, not everyone who follows a public figure's weight-loss journey online.

Private eligibility (the route available through a regulated online pharmacy) is broader: a BMI of 30 or above qualifies, as does a BMI from 27 upwards if a weight-related condition is present. Lower thresholds also apply for some ethnic backgrounds under UK clinical guidance. Even then, the prescriber assesses the full picture. BMI is a starting point, not a ticket. A clinical reviewer considers contraindications, existing medicines, thyroid history and much else before any treatment is approved.

One practical check you can do right now, before anything else: use the NHS BMI calculator to confirm your own number. It takes under a minute and gives you a concrete basis for the conversation with a prescriber, rather than working from an estimate.

For a broader look at the clinical detail behind tirzepatide, the tirzepatide overview on our site covers the mechanism and evidence in full.

Step 3: Separate the trial evidence from the anecdote

The results Lottie Moss and others describe are not invented. Tirzepatide genuinely produces meaningful weight loss in clinical trials, in real people, at scale. In SURMOUNT-1, which randomised 2,539 adults with obesity, those taking the 15mg dose lost an average of around 20–21% of body weight over 72 weeks. That is a substantial figure by the standards of any licensed medicine.

What the celebrity framing cannot show you is the distribution around that average. Some participants lost considerably more; others less. Results depend on dose, adherence, individual biology and the lifestyle changes taken alongside treatment, and if you want to understand the pharmacology in greater depth, the tirzepatide Medscape reference we link to is a useful place to read how clinicians approach the medicine. Clinical trials also involve regular monitoring, structured titration and careful adverse-event reporting. None of those things disappear when the medicine leaves a trial setting, which is why the prescriber relationship matters throughout treatment, not just at the start.

Common side effects are predominantly gastrointestinal: nausea, loose stools, constipation, indigestion and reduced appetite are the most reported. They tend to be most pronounced at the beginning of treatment or after a dose increase, and they ease for most people within the first couple of weeks at a given dose. The prescriber's role during titration is to manage that process, not simply to issue a pen and step back.

Step 4: What a legitimate private route looks like

If you have read this far because Lottie Moss's experience prompted a genuine question about whether Mounjaro might be right for you, the next step is a proper clinical consultation rather than further searching. Any regulated UK online pharmacy offering tirzepatide should appear on the GPhC pharmacy register, ours is registered under number 9012878, which you can verify directly. A prescriber, not a form, reads every consultation at nume. The pharmacy dispatches on the same working day if clinical approval follows, and delivery arrives free the next working day via tracked courier.

The Mounjaro treatment page covers eligibility, the assessment process and what is included in the price. There are no subscriptions and no automatic renewals, each repeat order goes through a fresh clinical review. If you are based in Ireland and want to understand how access works there, our guide to Mounjaro in Ireland sets out the relevant details. If you are thinking about where to start, the free consultation is the right first step, and our prescribers can tell you clearly whether tirzepatide is appropriate for your situation. Questions about specific aspects of treatment (including hormonal side effects or changes in urination that people notice) are exactly the kind of thing those conversations are for.